Arabian Ethicals partners with Accord Healthcare to advance patient access across the UAE
Arabian Ethicals, a Ghobash Group enterprise with nearly five decades of experience in supporting the UAE’s healthcare ecosystem, has announced a strategic partnership with Accord Healthcare, one of Europe’s fastest-growing pharmaceutical companies headquartered in the United Kingdom. The collaboration aims to enhance the availability and accessibility of essential cancer therapies and oncology treatments for patients across the UAE.
The partnership represents a significant step toward strengthening patient access to life-saving, high-quality treatments. Arabian Ethicals, a key player in the UAE healthcare supply chain, continues to support hospitals, clinics and pharmacies in both the public and private sectors. Its alliance with Accord Healthcare aligns with its strategic mission to expand access to essential treatments, elevate service standards and reinforce its standing as a trusted healthcare partner in the country.
Ebru Yavuz, General Manager of Arabian Ethicals, highlighted the organisation’s longstanding commitment to improving healthcare access. “This partnership reflects our commitment to widening access to essential treatments and consistently raising service standards across the UAE. Working with Accord Healthcare strengthens our ability to meet patient needs, particularly in critical areas such as oncology,” she said.
The collaboration leverages Arabian Ethicals’ market presence and Accord Healthcare’s extensive global portfolio, particularly in the field of oncology, where Accord has a strong heritage. Accord’s portfolio includes 37 oncology-related treatments, spanning key chemotherapy products used in the management of prevalent tumour types such as breast and prostate cancer, as well as treatments for hematological conditions and supportive oncology care.
Beyond expanding access to current therapies, the partnership will pave the way for introducing new innovations from Accord’s global pipeline. These include biosimilars and novel therapies developed through Accord Biopharma in London, a dedicated research and development facility focused on biologics and vaccines.
Hany Mashaal, Commercial Director MENA at Accord Healthcare, underscored the shared mission behind the partnership. “We are pleased to partner with Arabian Ethicals in expanding the availability of vital and affordable oncology and essential cancer therapies across the UAE. This collaboration supports our mission to ensure patients benefit from Accord’s global expertise in generics, biosimilars and oncology, and to deliver meaningful solutions that address evolving healthcare needs,” he said.
The agreement lays the foundation for a long-term collaboration aimed at supporting healthcare providers nationwide with reliable, high-quality treatment solutions. Both organisations reaffirmed their commitment to improving patient outcomes and driving progress in the UAE healthcare sector.
